Experimental validation via gene silencing demonstrated that suppression of PRKCSH effectively reduced malignant cell proliferation while promoting apoptotic mechanisms in lung cancer models.<h4>Conclusions</h4>This extensive investigation positioned PRKCSH as a critical prognostic biomarker and a promising therapeutic target for personalized immunotherapeutic strategies in the management of LUAD. Here, PRKCSH is linked to lung carcinoma.